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Editorial on the Research Topic
Glia in Health and Disease
Half a billion of years of evolution of the central nervous system (CNS) resulted in emergence
of two highly integrated and interconnected cellular networks (Verkhratsky and Nedergaard,
2016) of neurones (executive arm of the CNS) and neuroglia (CNS homoeostatic and defensive
division). Concerted activity of these networks underlies CNS function and output including
behavior, intelligence, emotions and consciousness. Evolutionary specialization produced division
of function in which neurones provide for information processing and creation of circuit-mediated
behavior, whereas neuroglia assume full responsibility for homeostatic support of the nervous
system. In addition, neuroglia provide (through conserved programmes of activation) for the
defense of the nervous tissue. These distinct functions are reflected by distinct physiology of these
two types of cells. Neuronal signaling relies on electrical excitabilitymediated by voltage-gated ionic
channels and fast (millisecond range) synaptic transmission. Glia employ controlled fluctuations
in intracellular ions and messengers; intercellular fluxes of these molecules underlie long-range
signaling in glial syncytia that occur (within seconds) in the form of propagated ionic or metabolic
(slow) waves (Verkhratsky and Nedergaard, 2018). Intercellular communications between the two
networks are mediated by chemical transmission and a complement of receptors; neuroglial cells
are capable to perceive neuronal activity and to secrete ions and signaling molecules [although
secretion mechanisms/tool sets differ from that in synaptic terminals—(Verkhratsky et al., 2016)].
The homeostatic and defensive capacity of neuroglia stipulates their fundamental role in
neuropathology. Conceptually, the glial component is present in every type of neurological
disease, with glial contribution being either primary and/or secondary. Astrocytes undergo several
types of pathological transformation from pathological remodeling and atrophy/degeneration
with a loss of function to astrogliotic transformation (Verkhratsky et al., 2013; Sofroniew,
2014b; Pekny et al., 2016; Verkhratsky and Parpura, 2016); the latter producing numerous
reactive phenotypes with neuroprotective or neurotoxic features (Pekny and Pekna, 2014;
Sofroniew, 2014a; Liddelow et al., 2017). Microglial cells, that constantly scan brain parenchyma
for damage or pathogen-associated molecular patterns, respond to lesions by highly complex
activation that produces multiple neuroprotective or neurotoxic phenotypes (Kettenmann et al.,
2011; Salter and Stevens, 2017). Finally, oligodendroglia and their precursors (also known as
NG2 glia) respond to pathology with Wallerian degeneration, proliferation, and remyelination
(Sun et al., 2010; Catenaccio et al., 2017).
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This Research Topic aims to address the role of neuroglia
in healthy and diseased nervous tissue through a collection of
28 articles that include 2 mini-reviews, 4 reviews, 1 opinion, 19
original research article, 1 Perspective, and 1 Protocol. These
articles provide a comprehensive overview on a broad spectrum
of molecular and cellular basis of glial function in normal and
pathological CNS.
The Research Topic discusses some of the physiological
functions of neuroglia. The opinion on Ca2+-dependent and
Ca2+-independent release of ATP from murine astrocytes
is discussed by Xiong et al. while several articles discuss
the regulation and molecular mechanisms of glial plasticity
(Boerboom et al.; Lalo et al.; Wang and Parpura). Glial
metabolism and other aspects of murine glial function were also
included. A new signaling pathway associated with extracellular
lactate, lactate receptor, and subsequent increase in cyclic-AMP
was found to modulate astroglial metabolism by enhancing
aerobic glycolysis (Vardjan et al.). In Zebrafish (Zhang et al.),
microglial cells were shown to mediate clearance of apoptotic
endothelial cells associated with vessel pruning. A novel
method to study micropinocytosis in fly, Drosophila, hemocytes,
phagocytic cells similar to microglia in mammals has been also
described (Chen et al.).
Both astrocytes and microglia contribute to acute pathology
such as ischemic stroke and epilepsy. Astrocytic Kir4.1, an
inwardly rectifying K+ channel, is central to regulation of K+
buffering to rebalance the blast of increased extracellular K+
concentration during ischemic conditions (Milton and Smith).
In ischaemic conditions, microglia get activated by microRNA
miR-145-5p/ Nuclear receptor related 1 protein (Nurr1)/Tumor
necrosis Factor-α cascade which can be used to define a
novel therapeutic strategy to relieve neuronal damage as a
consequence of microglial activation (Xuemei et al.). In the rat
lithium-pilocarpine model of status epilepticus (SE), a significant
reduction in the number of distal astrocytic branches were
detected upon SE induction, suggesting that astrocytic atrophy
correlates with SE-induced epileptic pathological conditions
(Plata et al.). During central post-stroke pain, the Stromal
cell-derived factor (SDF)-1 (CXC chemokine ligand-12)—
(CXC chemokine receptor CXCR4) signaling is up-regulated
and provide positive feedback to regulate glial-glial and glial-
neuronal interactions (Fei et al.). Astrocytes are also involved in
chronic pathologies; in particular they canmediate noradrenergic
pathways responsible for neurodegeneration and cognitive
decline in Alzheimer’s disease (Leanza et al.).
Microglia-mediated response of the CNS significantly
contributes to various chronic pathologies, including
neurodegeneration. Articles assembled in this Research
Topic indicate that microglial activation (induced by exposure
to lipopolysaccharide, LPS) can be ameliorated by the natural
plant compounds polyphenols and the glucagon like peptide-1
receptor (GLP-1R) agonist exendin-4 (EX-4) upon LPS exposure
(Gullo et al.). Similar effects were exerted by caffeine/modafinil
in a rat model of sleep deprivation; the treatment led to a
significant improvement of the anxious behavior (Wadhwa
et al.). As for the identification of molecular components
involved in microglia-mediated pathological processes, the
Dendritic cell-derived factor 1 (Dcf1), a factor in neural stem cell
differentiation, glioma apoptosis, and dendritic spine formation,
microglial lectins including galectins, siglecs, mannose-binding
lectins (MBLs) as well as other glycan binding proteins, all play
pivotal role in regulating microglia contribution to pathology
(Siew and Chern; Wang et al.).
Glia contribute to many diseases. For instance, methyl CpG
binding protein 2 (MeCP2) deficiency in various types of glia
causes various defects and anomalies that contribute to Rett
syndrome (Xu-Rui et al.). Activation of P2X7 purinoreceptor
triggers microglial response through autophagy and mammalian
target of rapamycin (mTOR) pathway in amyotrophic lateral
sclerosis (ALS) mouse model with mutated (G93A) superoxide
dismutase; this signaling cascade could represent a potential
target for modulating ALS progression (Fabbrizio et al.).
Microglial expression of lipoprotein lipase is required for
supporting remyelination and repair through the clearance
of lipid debris, a feature crucial for demyelinating disorders,
including multiple sclerosis (Bruce et al.). An overview on the
proteomic and metabolic profiling of vanishing white matter
mouse astrocytes has been provided by Wisse et al.
The cell adhesion molecule with homology to L1 (CHL1)
promotes cell proliferation, metastasis and migration in
human glioma cells both in vitro and in vivo (Yang et al.).
The origin of glioblastomas can be potentially associated wit
adult neural stem cells (NSCs) and oligodendrocyte precursor
cells (OPCs) serving as cells of origin for glioblastoma, as
reviewed by Shao and Lui. In this aspect, another important
finding demonstrates that ryanodine receptors (RyR3) mediate
Ca2+ release from the endoplasmic reticulum in order to
regulate OPC differentiation (Li et al.). Several other factors
affect glial transformations. B-cell chronic lymphocytic
leukemia (CLL)/lymphoma 11B f(Bcl11b) protein, a C2H2-
type zinc finger transcriptional factor, negatively regulates
glial progenitor cell differentiation through the repression
of oligodendrocyte differentiation-associated genes (Wang
et al.), whereas epithelial growth factor (EGF) enhances
oligodendrocyte differentiation from glial progenitor cells (Yang
et al.). Finally, Cloarec and colleagues show that administration
of clodronate liposomes or maternal feeding with doxycyline,
both result in alternation of microglial activity and abundance,
improved survival in a rate model of cytomegalovirus infection
(Cloarec et al.).
Glial cells were long thought to serve merely as the supporting
cast and scenery behind the neuronal stars of the show. Relatively
recent evidence, however, indicates that the glial cells are
intimately involved in many of the brain’s functions in health
and disease. The intent of this Research Topic was to provide an
update on recent developments in glial biology be that in health
and disease.
AUTHOR CONTRIBUTIONS
All four authors contribute in writing the editorial and organizing
the research topic.
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 March 2019 | Volume 12 | Article 63
Ho et al. Editorial: Glia in Health and Disease
REFERENCES
Catenaccio, A., Llavero Hurtado, M., Diaz, P., Lamont, D. J., Wishart, T.
M., and Court, F. A. (2017). Molecular analysis of axonal-intrinsic and
glial-associated co-regulation of axon degeneration. Cell Death Dis. 8:e3166.
doi: 10.1038/cddis.2017.489
Kettenmann, H., Hanisch, U. K., Noda, M., and Verkhratsky, A. (2011). Physiology
of microglia. Physiol. Rev. 91, 461–553. doi: 10.1152/physrev.00011.2010
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C.
J., Schirmer, L., et al. (2017). Neurotoxic reactive astrocytes are induced by
activated microglia. Nature 541, 481–487. doi: 10.1038/nature21029
Pekny, M., and Pekna, M. (2014). Astrocyte reactivity and reactive
astrogliosis: costs and benefits. Physiol. Rev. 94, 1077–1098.
doi: 10.1152/physrev.00041.2013
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J. M., Parpura, V., et al.
(2016). Astrocytes: a central element in neurological diseases.Acta Neuropathol.
131, 323–345. doi: 10.1007/s00401-015-1513-1
Salter, M. W., and Stevens, B. (2017). Microglia emerge as central players in brain
disease. Nat. Med. 23, 1018–1027. doi: 10.1038/nm.4397
Sofroniew, M. V. (2014a). Astrogliosis. Cold Spring Harb Perspect Biol. 7:a020420.
doi: 10.1101/cshperspect.a020420
Sofroniew, M. V. (2014b). Multiple roles for astrocytes as effectors of
cytokines and inflammatory mediators. Neuroscientist 20, 160–172.
doi: 10.1177/1073858413504466
Sun, F., Lin, C. L., McTigue, D., Shan, X., Tovar, C. A., Bresnahan, J. C., et al. (2010).
Effects of axon degeneration on oligodendrocyte lineage cells: dorsal rhizotomy
evokes a repair response while axon degeneration rostral to spinal contusion
induces both repair and apoptosis. Glia 58, 1304–1319. doi: 10.1002/glia.21009
Verkhratsky, A., Matteoli, M., Parpura, V., Mothet, J. P., and Zorec, R. (2016).
Astrocytes as secretory cells of the central nervous system: idiosyncrasies of
vesicular secretion. EMBO J. 35, 239–257. doi: 10.15252/embj.201592705
Verkhratsky, A., and Nedergaard, M. (2016). The homeostatic astroglia emerges
from evolutionary specialization of neural cells. Philos. Trans. R Soc. Lond. B
Biol. Sci. 371:20150428. doi: 10.1098/rstb.2015.0428
Verkhratsky, A., and Nedergaard, M. (2018). Physiology of Astroglia. Physiol. Rev.
98, 239–389. doi: 10.1152/physrev.00042.2016
Verkhratsky, A., and Parpura, V. (2016). Astrogliopathology in
neurological, neurodevelopmental and psychiatric disorders.
Neurobiol. Dis. 85, 254–261. doi: 10.1016/j.nbd.2015.
03.025
Verkhratsky, A., Rodríguez, J. J., and Parpura, V. (2013). Astroglia in neurological
diseases. Future Neurol. 8, 149–158. doi: 10.2217/fnl.12.90
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Ho, Verkhratsky, Duan and Parpura. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 March 2019 | Volume 12 | Article 63
